Keyword: Eli Lilly


Eli Lilly ditches NextCure pact

Eli Lilly has killed off its deal with immuno-oncology biotech NextCure after spending $25 million upfront on the pact just over a year ago.
Eli Lilly

30. Reyvow

Reyvow, a first-in-class drug Lilly picked up with its 2017 CoLucid buyout, won approval in the fall to treat migraines as they occur.